Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

Roche’s Kad­cy­la has be­come the first an­ti­body-drug con­ju­gate to en­ter the Chi­nese mar­ket, mark­ing a dra­mat­ic ad­vance for both the Swiss phar­ma gi­ant and the ther­a­peu­tic class.

The lo­cal arm of Roche an­nounced the ap­proval late Tues­day, which cov­ers the ther­a­py’s use in the ad­ju­vant set­ting in pa­tients with ear­ly HER-2 pos­i­tive breast can­cer who still have resid­ual in­va­sive dis­ease af­ter re­ceiv­ing pa­cli­tax­el and Her­ceptin as neoad­ju­vant treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER